DEB-TACE for Conventional TACE Refractory Patients

DOI
  • Minami Testuya
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Sanada Junichiro
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Kobayashi Satoshi
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Koda Wataru
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Kozaka Kazuto
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Kitao Azusa
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Inoue Dai
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Yoshida Kotaro
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Yoneda Norihide
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Ikeno Hiroshi
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Okumura Kenichiro
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Gabata Toshifumi
    Department of Radiology, Kanazawa University Graduate School of Medical Science
  • Matsui Osamu
    Department of Radiology, Kanazawa University Graduate School of Medical Science

Bibliographic Information

Other Title
  • Conventional TACE不応肝細胞癌症例に対するDEB-TACE

Search this article

Description

Hepatocellular carcinoma is a particularly common malignancy in Asian countries. In Japan, trans-arterial chemoembolization (TACE) is usually given to patients with intermediate stage hepatocellular carcinoma and conventional transcatheter arterial chemoembolization (cTACE) is the gold standard for the treatment of this stage. cTACE has been performed using lipiodol emulsion mixed with anticancer drugs followed by gelatin sponge particles. After several sessions of cTACE, some patients become refractory to this TACE. From the aspect of world standards, sorafenib is recommended for use in HCC patients who are refractory to TACE with well-preserved liver function. From early 2014, drug eluting beads (DEB) have become commercially available in Japan at last. However use of these new products for HCC treatment has only just begun in Japan. Here, we describe the current status of DEB-TACE for cTACE refractory patients in our limited experience.

Journal

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top